An advantage of this approach is that there is an already established arsenal of STAT3 and STAT5 inhibitors, which are currently under investigation for the treatment of cancer or autoimmune diseases, as reviewed in detail by Loh and colleagues [40]. The gene discussed is STAT5A; the disease is autoimmune disease.